Skip to content

Effect of long-acting erythropoietin and roxarestat on haemoglobin compliance in maintenance haemodialysis patients

Effect of long-acting erythropoietin and roxarestat on haemoglobin compliance in maintenance haemodialysis patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078632
Enrollment
Unknown
Registered
2023-12-14
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance hemodialysis

Interventions

Rosastat group:No
DPO-a group:No

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Be 20 years of age or older 2) Receiving three stable HD treatments per week and stable dialysis for more than 12 weeks 3) Meet the diagnosis of renal anaemia 4) Signed informed consent 5) Haemoglobin 6-12g/dL

Exclusion criteria

Exclusion criteria: 1) Patients with malignant tumours, such as prostate cancer, breast cancer, renal cell carcinoma, etc. 2)High blood pressure which is difficult to control (3) Elevated ALT, AST greater than 3 times the upper limit of normal value, and total bilirubin greater than 2 times the upper limit of normal value. (4) Any other anaemia caused by diseases other than CKD, such as thalassaemia, sickle cell anaemia, red blood cell anaemia, haemolytic anaemia, tumour-related anaemia, chemotherapy-related anaemia, and myelodysplastic syndromes. (5) cardiac function class III or IV congestive heart failure, liver failure of the Heart Association 6)Active or significant serious infections (7) Hemoglobin without regular follow-up after treatment.

Design outcomes

Primary

MeasureTime frame
Mean haemoglobin maintained at 10-12 g/dL at 12-16 weeks;

Secondary

MeasureTime frame
Changes in haemoglobin;

Countries

China

Contacts

Public ContactWan Qijun

Shenzhen Second People's Hospital

yiyuan2224@sina.com+86 135 3785 7368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026